| __timestamp | Johnson & Johnson | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 22746000000 | 9136000 |
| Thursday, January 1, 2015 | 21536000000 | 5807000 |
| Friday, January 1, 2016 | 21685000000 | 5571000 |
| Sunday, January 1, 2017 | 25354000000 | 5366000 |
| Monday, January 1, 2018 | 27091000000 | 6337000 |
| Tuesday, January 1, 2019 | 27556000000 | 11347000 |
| Wednesday, January 1, 2020 | 28427000000 | 30419000 |
| Friday, January 1, 2021 | 23402000000 | 62176000 |
| Saturday, January 1, 2022 | 24596000000 | 52827000 |
| Sunday, January 1, 2023 | 26553000000 | 35049000 |
| Monday, January 1, 2024 | 27471000000 |
In pursuit of knowledge
In the ever-evolving landscape of the pharmaceutical industry, understanding cost dynamics is crucial. Johnson & Johnson, a titan in the sector, has consistently demonstrated robust cost management. From 2014 to 2023, their cost of revenue has shown a steady increase, peaking in 2020 with a 25% rise from 2014. This trend reflects their expansive operations and strategic investments.
Conversely, Ligand Pharmaceuticals Incorporated, a smaller player, presents a different narrative. Their cost of revenue surged dramatically, especially between 2019 and 2021, with a staggering 448% increase. This spike highlights their aggressive growth strategies and potential scaling challenges.
These contrasting trends offer a fascinating glimpse into how companies of different scales navigate financial pressures. As the industry continues to evolve, monitoring these cost dynamics will be essential for stakeholders and investors alike.
Cost of Revenue: Key Insights for Eli Lilly and Company and Ligand Pharmaceuticals Incorporated
Cost of Revenue Comparison: Johnson & Johnson vs Regeneron Pharmaceuticals, Inc.
Johnson & Johnson vs Viatris Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Johnson & Johnson and Cytokinetics, Incorporated's Expenses
Johnson & Johnson vs Agios Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Ligand Pharmaceuticals Incorporated
Cost of Revenue: Key Insights for Biogen Inc. and Ligand Pharmaceuticals Incorporated
Cost of Revenue Comparison: United Therapeutics Corporation vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: Jazz Pharmaceuticals plc and Ligand Pharmaceuticals Incorporated
Cost Insights: Breaking Down Ligand Pharmaceuticals Incorporated and MiMedx Group, Inc.'s Expenses